v3 Template
I

Immutrin

Biotechnology ~300 employees
Founded
--
Employees (Est.)
~300
15 leaders known
Total Funding
$87.0M
Funding Rounds
1
Last Funding
2026-03-24

About Immutrin

Immutrin is a biotechnology company focused on developing next-generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis, with a lead asset targeting ATTR cardiomyopathy.

Products & Services

Lead Antibody Therapy:A potential best-in-class therapy for ATTR cardiomyopathy with a unique mechanism to selectively remove established amyloid fibrils.

Specialties

Antibody Therapy Amyloidosis Treatment ATTR Cardiomyopathy

Funding History

Debug: View Raw Funding Data
# Type Amount Fields Date Fields Investors
1 RT: Series A
T: -
FT: Series A 		A: 87000000
MR: -
FA: £65 million
FAN: 87000000 		D: 2026-03-24
FD: 2026-03-24 		6 investors
Series A Latest
2026-03-24
$87.0M
6 investors (Pro only)

Growth Metrics

+45%
Employee Growth
YoY
3.2x
Funding Growth
Last Round
12
Markets
Operating
10K+
Customers
Active

View 3 more growth metrics with Pro

Unlock All Metrics
Mock Up

Team & Leadership

M

Mihriban Tuna

CEO

LinkedIn (Pro only)
T

Tolga Hassan

CFO and COO

LinkedIn (Pro only)
K

Kin Mei Leung

VP R&D

LinkedIn (Pro only)
S

Sef Kurstjens

CHAIR

J

James N. Topper

Managing Partner

N

Nihal Sinha

Partner

View 12 more team members with Pro

Unlock Full Team Directory

Recent News

Immutrin Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Read more →

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Read more →

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Read more →

View 2 more news articles with Pro

Unlock Full News Feed
Mock Up

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised

Mock Up

Company Details

Industries
Biotechnology
Company Size
~300 employees (est.)

Similar Companies

Discover AI-powered company recommendations based on industry, funding, and team profiles.

Upgrade to Pro

Technology Stack

Discover the backend, frontend, and infrastructure technologies powering this company's products.

Upgrade to Pro